Abstract: The present invention provides a live, attenuated coronavirus comprising a mutation in non-structural protein nsp-3 and/or deletion of accessory proteins 3a and 3b. The coronavirus may be used as a vaccine for treating and/or preventing a disease, such as infectious bronchitis, in a subject.
Type:
Application
Filed:
January 26, 2017
Publication date:
January 24, 2019
Inventors:
Erica Bickerton, Sarah Keep, Paul Britton
Abstract: The present invention provides a live, attenuated coronavirus comprising a mutation in non-structural protein nsp-3 and/or deletion of accessory proteins 3a and 3b. The coronavirus may be used as a vaccine for treating and/or preventing a disease, such as infectious bronchitis, in a subject.
Type:
Grant
Filed:
January 26, 2017
Date of Patent:
December 21, 2021
Assignee:
THE PIRBRIGHT INSTITUTE
Inventors:
Erica Bickerton, Sarah Keep, Paul Britton
Abstract: The present invention provides a live, attenuated coronavirus comprising a variant replicase gene encoding polyproteins comprising a mutation in one or more of non-structural protein(s) (nsp)-10, nsp-14, nsp-15 or nsp-16. The coronavirus may be used as a vaccine for treating and/or preventing a disease, such as infectious bronchitis, in a subject.
Type:
Application
Filed:
July 23, 2015
Publication date:
August 3, 2017
Inventors:
Erica Bickerton, Sarah Keep, Paul Britton
Abstract: The present invention provides a live, attenuated coronavirus comprising a variant replicase gene encoding polyproteins comprising a mutation in one or more of non-structural protein(s) (nsp)-10, nsp-14, nsp-15 or nsp-16. The coronavirus may be used as a vaccine for treating and/or preventing a disease, such as infectious bronchitis, in a subject.
Type:
Grant
Filed:
July 23, 2015
Date of Patent:
November 20, 2018
Assignee:
THE PIRBRIGHT INSTITUTE
Inventors:
Erica Bickerton, Sarah Keep, Paul Britton
© 2024 Justia
